739 related articles for article (PubMed ID: 16400359)
1. Infliximab for treatment of pyoderma gangrenosum associated with clinically inactive Crohn's disease. A case report.
Kouklakis G; Moschos J; Leontiadis GI; Kadis S; Mpoumponaris A; Molyvas E; Minopoulos GI
Rom J Gastroenterol; 2005 Dec; 14(4):401-3. PubMed ID: 16400359
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Pyoderma gangrenosum associated with Crohn's disease.
Zaccagna A; Bertone A; Puiatti P; Picciotto F; Sprujevnik T; Santucci R; Rossini FP
Eur J Dermatol; 2003; 13(3):258-60. PubMed ID: 12804985
[TBL] [Abstract][Full Text] [Related]
3. Use of infliximab in pyoderma gangrenosum.
Hewitt D; Tait C
Australas J Dermatol; 2007 May; 48(2):95-8. PubMed ID: 17535196
[TBL] [Abstract][Full Text] [Related]
4. Infliximab for the treatment of disseminated pyoderma gangrenosum associated with ulcerative colitis. Case report and literature review.
Juillerat P; Christen-Zäch S; Troillet FX; Gallot-Lavallée S; Pannizzon RG; Michetti P
Dermatology; 2007; 215(3):245-51. PubMed ID: 17823524
[TBL] [Abstract][Full Text] [Related]
5. Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody.
Tan MH; Gordon M; Lebwohl O; George J; Lebwohl MG
Arch Dermatol; 2001 Jul; 137(7):930-3. PubMed ID: 11453813
[TBL] [Abstract][Full Text] [Related]
6. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease.
Regueiro M; Valentine J; Plevy S; Fleisher MR; Lichtenstein GR
Am J Gastroenterol; 2003 Aug; 98(8):1821-6. PubMed ID: 12907338
[TBL] [Abstract][Full Text] [Related]
7. Favorable response to infliximab treatment in a patient with active Crohn disease and pyoderma gangrenosum.
Triantafillidis JK; Cheracakis P; Sklavaina M; Apostolopoulou K
Scand J Gastroenterol; 2002 Jul; 37(7):863-5. PubMed ID: 12190104
[TBL] [Abstract][Full Text] [Related]
8. Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome.
Stichweh DS; Punaro M; Pascual V
Pediatr Dermatol; 2005; 22(3):262-5. PubMed ID: 15916580
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic hotline. Infliximab for treatment of resistant pyoderma gangrenosum associated with ulcerative colitis and psoriasis. A case report.
Baglieri F; Scuderi G
Dermatol Ther; 2010; 23(5):541-3. PubMed ID: 20868408
[TBL] [Abstract][Full Text] [Related]
10. Pyoderma gangrenosum outside the context of inflammatory bowel disease treated successfully with infliximab.
Swale VJ; Saha M; Kapur N; Hoffbrand AV; Rustin MH
Clin Exp Dermatol; 2005 Mar; 30(2):134-6. PubMed ID: 15725238
[TBL] [Abstract][Full Text] [Related]
11. Corticosteroid-resistant pyoderma gangrenosum associated with Crohn's disease: rapid cure with infliximab.
Grange F; Djilali-Bouzina F; Weiss AM; Polette A; Guillaume JC
Dermatology; 2002; 205(3):278-80. PubMed ID: 12399677
[TBL] [Abstract][Full Text] [Related]
12. Infliximab for treatment of resistant pyoderma gangrenosum associated with Crohn's disease.
Ferkolj I; Hocevar A; Golouh R; Dolenc Voljc M
Acta Dermatovenerol Alp Pannonica Adriat; 2006 Dec; 15(4):173-7. PubMed ID: 17982610
[TBL] [Abstract][Full Text] [Related]
13. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
14. Treatment of idiopathic pyoderma gangrenosum with infliximab: induction dosing regimen or on-demand therapy?
Adişen E; Oztaş M; Gürer MA
Dermatology; 2008; 216(2):163-5. PubMed ID: 18216480
[TBL] [Abstract][Full Text] [Related]
15. Superficial granulomatous pyoderma treated preoperatively with infliximab.
Akhras V; Sarkany R; Walsh S; Hyde N; Marsden RA
Clin Exp Dermatol; 2009 Jul; 34(5):e183-5. PubMed ID: 19094137
[TBL] [Abstract][Full Text] [Related]
16. Scrotal pyoderma gangrenosum associated with Crohn's disease.
Ho SA; Tan WP; Tan AW; Wong SN; Chua SH
Singapore Med J; 2009 Dec; 50(12):e397-400. PubMed ID: 20087538
[TBL] [Abstract][Full Text] [Related]
17. Infliximab for peristomal pyoderma gangrenosum.
Mimouni D; Anhalt GJ; Kouba DJ; Nousari HC
Br J Dermatol; 2003 Apr; 148(4):813-6. PubMed ID: 12752145
[TBL] [Abstract][Full Text] [Related]
18. Treatment of pyoderma gangrenosum with infliximab in Crohn's disease.
Sapienza MS; Cohen S; Dimarino AJ
Dig Dis Sci; 2004 Sep; 49(9):1454-7. PubMed ID: 15481318
[TBL] [Abstract][Full Text] [Related]
19. Rapid improvement of pyoderma gangrenosum after treatment with infliximab.
Chan JL; Graves MS; Cockerell CJ; Pandya AG
J Drugs Dermatol; 2010 Jun; 9(6):702-4. PubMed ID: 20645536
[TBL] [Abstract][Full Text] [Related]
20. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease.
de Rossi TM; Krauss N; Voll RE; Nägel A; Weidenhiller M; Konturek PC; Hahn EG; Raithel M
Digestion; 2008; 78(4):195-200. PubMed ID: 19122456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]